Is Curative‐Intent Primary Surgery Beneficial for Geriatric Oral Cavity Squamous Cell Carcinoma Patients?
Head & Neck · 15.07.2026
DOI: 10.1002/hed.70399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 15.07.2026. Verfasst von Ya-Wei Hsiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial, Linkou, Taiwan. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital, Linkou, National Science and Technology Council.
Abstract (Originalsprache)
Introduction
Given the increasing incidence of oral cavity squamous cell carcinoma (OCSCC) among elderly patients, the optimal treatment for the elderly remains controversial. This study aimed to compare clinical features and outcomes between elderly (≥ 70 years) and younger patients with OCSCC undergoing curative surgery, focusing on the prognostic impact of age and tumor‐related factors. Material and Methods In this single‐center retrospective study, patients aged ≥ 40 years who underwent curative resection for OCSCC between May 1996 and September 2023 were included. All received ≥ 1 cm surgical margins and neck dissection. Patients were stratified by age (40–69 years vs. ≥ 70 years). Clinicopathologic and treatment variables were compared between groups. Survival outcomes including 5‐year disease‐free survival (DFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression models.
Results
Among 1744 OCSCC patients included, 1622 (93.0%) were 40–69 years and 122 (7.0%) were ≥ 70 years. Elderly patients had significantly better 5‐year DFS ( p = 0.035), while OS was comparable between groups ( p = 0.495). Multivariable analysis showed age ≥ 70 years was independently associated with improved DFS (HR: 0.644; p = 0.044), but not OS (HR: 1.153; p = 0.392). Advanced T stage (HR: 1.757), nodal metastasis with extra‐nodal extension (ENE) (HR: 2.443), and lymphatic invasion (HR: 1.969) were strong independent predictors of worse OS (all p < 0.001).
Conclusion
Carefully selected elderly OCSCC patients can achieve comparable OS and even favorable DFS. Prognosis is more strongly influenced by tumor‐related pathological factors than by age, supporting treatment decisions for surgery‐eligible elder patients based on functional reserve, overall health, and tumor biology rather than chronological age alone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial, Linkou, Taiwan.
- ENT Department, Akdeniz University Medical Faculty in Antalya, Antalya, Turkey.
- Department of Medical Education, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Medical College, Chang Gung University, Taoyuan, Taiwan.
- Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial, Keelung Branch, Keelung, Taiwan.
- Department of Otolaryngology, Hsin-Chu MacKay Memorial Hospital, Hsin-Chu, Taiwan.
ORCID-Profile: Ya-Wei Hsiao, Levent Renda, Chi-Kuang Young, Chih-Yung Yang, Chun-Ta Liao, Shiang-Fu Huang
Förderung
- Chang Gung Memorial Hospital, Linkou
- National Science and Technology Council
Zitieren
APA
Hsiao, Y. W., Renda, L., Chen, H. L., Young, C. K., Yang, C. Y., Hu, Y. F., Liao, C. T., Tsao, C. K., & Huang, S. F. (2026). Is Curative‐Intent Primary Surgery Beneficial for Geriatric Oral Cavity Squamous Cell Carcinoma Patients?. Head & Neck. https://doi.org/10.1002/hed.70399
Vancouver
Hsiao YW, Renda L, Chen HL, Young CK, Yang CY, Hu YF, et al. Is Curative‐Intent Primary Surgery Beneficial for Geriatric Oral Cavity Squamous Cell Carcinoma Patients?. Head & Neck. 2026. doi:10.1002/hed.70399
BibTeX
@article{Hsiao2026,
author = {Hsiao, Ya-Wei and Renda, Levent and Chen, Huai-Liang and Young, Chi-Kuang and Yang, Chih-Yung and Hu, Yu-Feng and Liao, Chun-Ta and Tsao, Chung-Kan and Huang, Shiang-Fu},
title = {Is Curative‐Intent Primary Surgery Beneficial for Geriatric Oral Cavity Squamous Cell Carcinoma Patients?},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70399}
}
EUVIMED